Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VEGZELMA vs PORTRAZZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
VEGZELMA (bevacizumab-awwb) is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby reducing angiogenesis and tumor vascularization.
PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Metastatic colorectal cancer (first-line with IFL regimen),Metastatic colorectal cancer (first-line with FOLFOX regimen),Metastatic colorectal cancer (second-line with FOLFOX),Non-squamous non-small cell lung cancer (first-line with carboplatin/paclitaxel),Glioblastoma (as single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (with interferon alfa),Cervical cancer (with paclitaxel/cisplatin or paclitaxel/topotecan),Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (with paclitaxel, pegylated liposomal doxorubicin, or topotecan),Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (with carboplatin/paclitaxel or carboplatin/gemcitabine)
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
Intravenous infusion, 240 mg every 2 weeks or 480 mg every 4 weeks.
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
Terminal half-life: 11-14 hours (supports twice-daily dosing; no significant accumulation with normal renal function)
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Bevacizumab undergoes proteolytic degradation via general protein catabolism; no specific metabolic enzymes are involved.
Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways.
Renal: 70% (metabolites); Fecal: 30% (unchanged drug and metabolites)
Necitumumab is an Ig G1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
97% (primarily to albumin; minimal binding to alpha-1-acid glycoprotein)
Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported.
0.3-0.5 L/kg (indicates limited extravascular distribution, primarily confined to plasma and interstitial fluid)
Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution.
Subcutaneous: 60-80% (compared to intravenous); oral: not available (not orally bioavailable)
Intravenous: 100% (not applicable to other routes).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (Cr CL <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data.
Safety and efficacy not established in pediatric patients.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment required; monitor for increased incidence of adverse reactions, particularly hypertension and infusion-related reactions.
No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients.
Serious and sometimes fatal gastrointestinal perforation, wound dehiscence, hemorrhage, and arterial thromboembolic events (including stroke, myocardial infarction) have been reported. Therapy should be discontinued in patients who develop these complications.
No black box warnings.
Gastrointestinal perforation; surgery and wound healing complications (discontinue at least 28 days prior to elective surgery); hemorrhage (severe/fatal pulmonary hemorrhage in NSCLC); arterial thromboembolic events; proteinuria; hypertensive crisis; posterior reversible encephalopathy syndrome; infusion reactions; increased risk of ovarian failure; congestive heart failure.
Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities.,Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs.,Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs.,Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected.,Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly.,Infusion-related reactions; interrupt or discontinue for severe reactions.,Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose.,Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception.
None known.
No known contraindications from the manufacturer.
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice if also taking CYP3A4 substrates (though not directly studied with VEGZELMA).
No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis.
VEGZELMA (bevacizumab-awwb) is a VEGF inhibitor. Based on mechanism of action and findings in animal studies (rabbits at doses ≥10 mg/kg every 3 days), there is evidence of teratogenicity including increased rates of fetal malformations (e.g., cleft palate, skeletal abnormalities) and embryofetal mortality. In humans, first trimester exposure is not recommended due to risk of teratogenicity. Second and third trimester exposure may be associated with fetal growth restriction, oligohydramnios, and potential fetal renal impairment. No adequate human studies exist; use only if benefit justifies risk.
Portrazza (necitumumab) is an Ig G1 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
No human data on presence in breast milk. Bevacizumab is a large protein (MW ~149 k Da), likely to be excreted in low amounts. M/P ratio unknown. Potential for absorption and systemic effects in infant is low but cannot be excluded. Manufacturer advises to discontinue breastfeeding during therapy and for at least 6 months after last dose.
It is not known whether necitumumab is excreted in human milk. Human Ig G is known to be present in milk, but the amount is generally low. Due to the potential for serious adverse reactions in nursing infants, advise women not to breast-feed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
No established dose adjustments for pregnancy. Due to risks, avoid use in pregnancy unless benefit outweighs risk. If used, dose remains same as for non-pregnant adults (e.g., 5 mg/kg IV every 2 weeks). Monitor for increased clearance in second and third trimester; however, no formal PK studies in pregnancy. Consider therapeutic drug monitoring if available.
No specific dosing adjustments for pregnancy are established. However, physiological changes during pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics. Currently, no dose modification is recommended due to lack of data; however, caution is advised, and treatment should only be used if the potential benefit justifies the potential risk to the fetus.
VEGZELMA (bevacizumab-adcd) is a bevacizumab biosimilar. Monitor blood pressure regularly due to risk of hypertension. Assess urine protein via dipstick before each dose; hold for ≥2 g proteinuria. Increased risk of arterial thromboembolic events (ATE) in patients >65 years or with prior ATE. Do not administer within 28 days of major surgery. Discontinue for GI perforation, wound dehiscence, or severe hemorrhage.
PORTRAZZA (necitumumab) is a human Ig G1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors.
Report any new or worsening hypertension, severe headache, or blurred vision.,Notify your doctor if you experience unusual bleeding, bruising, or blood in urine or stool.,Avoid invasive dental procedures and inform your dentist about this medication.,Use reliable contraception during treatment and for at least 6 months after the last dose.,Seek immediate medical attention for sudden chest pain, shortness of breath, or leg swelling.
Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment.,Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat.,Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity.,Do not receive live vaccines while on PORTRAZZA.,Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VEGZELMA vs PORTRAZZA, answered by our medical review team.
VEGZELMA is a Antineoplastic Monoclonal Antibody that works by VEGZELMA (bevacizumab-awwb) is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby reducing angiogenesis and tumor vascularization.. PORTRAZZA is a Antineoplastic Monoclonal Antibody that works by PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VEGZELMA and PORTRAZZA depend on the specific clinical indication. These are both Antineoplastic Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VEGZELMA is: Intravenous infusion, 240 mg every 2 weeks or 480 mg every 4 weeks.. The standard adult dose of PORTRAZZA is: PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VEGZELMA and PORTRAZZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VEGZELMA is classified as Category C. VEGZELMA (bevacizumab-awwb) is a VEGF inhibitor. Based on mechanism of action and findings in animal studies (rabbits at doses ≥10 mg/kg every 3 days), there is evidence of teratog. PORTRAZZA is classified as Category C. Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to the. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.